Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | TUBB4A | P04350 | 10/20 | 0.53 |
| ▸ | TUBB | P07437 | 10/20 | 0.53 |
| ▸ | TUBA3C | P0DPH7 | 10/20 | 0.53 |
| ▸ | TUBA1B | P68363 | 10/20 | 0.53 |
| ▸ | TUBA4A | P68366 | 10/20 | 0.53 |
| ▸ | TUBB4B | P68371 | 10/20 | 0.53 |
| ▸ | TUBB3 | Q13509 | 10/20 | 0.53 |
| ▸ | TUBB2A | Q13885 | 10/20 | 0.53 |
| ▸ | TUBB8 | Q3ZCM7 | 10/20 | 0.53 |
| ▸ | TUBA3E | Q6PEY2 | 10/20 | 0.53 |
| ▸ | TUBA1A | Q71U36 | 10/20 | 0.53 |
| ▸ | TUBA1C | Q9BQE3 | 10/20 | 0.53 |
| ▸ | TUBB6 | Q9BUF5 | 10/20 | 0.53 |
| ▸ | TUBB2B | Q9BVA1 | 10/20 | 0.53 |
| ▸ | TUBB1 | Q9H4B7 | 10/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4423924 | 0.92 | EGFR (0.66) | EGFRTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL1683745 | 0.83 | KDM4E (0.51) | EGFRTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL1683769 | 0.81 | HDAC1 (0.52) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1683679 | 0.81 | EGFR (0.57) | EGFRTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL1683596 | 0.80 | TUBB4A (0.50) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1683666 | 0.80 | NEK2 (0.47) | EGFRTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL1683635 | 0.80 | HDAC1 (0.52) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1683677 | 0.80 | HDAC1 (0.51) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL722625 | 0.80 | ALDH1A1 (0.51) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4414241 | 0.80 | TUBB4A (0.60) | EGFRTUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10865196-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2020-12-15 | — | — | US | disclosed |
| US-10301285-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20190092755-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2019-03-28 | — | — | US | disclosed |
| US-20180093971-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2018-04-05 | — | — | US | disclosed |
| EP-3289876-A1 | COMPOUNDS FOR TREATMENT OF CANCER | University of Tennessee Research Foundation (US) | 2018-03-07 | — | — | EP | disclosed |
| EP-2959900-A1 | COMPOUND FOR TREATMENT OF CANCER | University of Tennessee Research Foundation (US) | 2015-12-30 | — | — | EP | disclosed |
| US-9029408-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140213623-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8592465-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-11-26 | — | — | US | disclosed |
| US-20090326020-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326020-A1 | COMPOUNDS FOR TREATMENT OF CANCER | HCCS, NQO1, CCNY | EGFR 263/4885TUBB4A 2060/4885TUBB 2030/4885 |
| US-10865196-B2 | Compounds for treatment of cancer | CYP19A1, CYP17A1, SOX18 | EGFR 520/4885TUBB4A 237/4885TUBB 461/4885 |
| US-10301285-B2 | Compounds for treatment of cancer | CYP19A1, CYP17A1, SOX18 | EGFR 520/4885TUBB4A 237/4885TUBB 461/4885 |
| US-20140213623-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CYP19A1, CYP17A1, SOX18 | EGFR 520/4885TUBB4A 237/4885TUBB 461/4885 |
| US-20180093971-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CYP19A1, CYP17A1, SOX18 | EGFR 520/4885TUBB4A 237/4885TUBB 461/4885 |
| US-20190092755-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CYP19A1, CYP17A1, SOX18 | EGFR 520/4885TUBB4A 237/4885TUBB 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.